Why the study?
Does the DiagCor GenoFlow Thrombophilia Array Test kit accurately detect thrombophilia-related mutations compared to Sanger sequencing in female patients with prior pregnancy complications?
Does the DiagCor GenoFlow Thrombophilia Array Test kit accurately detect thrombophilia-related mutations compared to Sanger sequencing in female patients with prior pregnancy complications?
The GenoFlow Thrombophilia Array Test kit is highly accurate, demonstrating 100% sensitivity and specificity for detecting common thrombophilia mutations in women with pregnancy complications.
Supports GenoFlow kit accuracy in this population; leaves open prospective validation before clinical adoption.
Thrombophilia is a heritable blood disease characterized by an increased tendency to form abnormal blood clots that can block blood vessels. In obstetrics and gynecology, it has been shown by a number of reports that a proportion of recurrent miscarriages involve thrombophilia-related mutations, in particular, Factor V G1691A, prothrombin G20210A, and MTHFR C677T and A1298C. In this study, we examined the frequency of these four mutations in 113 female Turkish patients who had prior complications in pregnancy, using the DiagCor GenoFlow Thrombophilia Array Test kit. Heterozygous MTHFR C677T and A1298C mutations were detected in 46% of the patients, and among these patients, 60% of them carried double heterozygous mutations. In contrast, the heterozygous Factor V G1691A and prothrombin G20210A were detected only in a smaller number of patients, respectively, 13% and 3%. The GenoFlow kit demonstrated 100% concordance with results from Sanger sequencing, which can be translated into sensitivity and specificity both at 100% within this series of patients.
No takes yet. Share an insight, caveat, or question.
Aytekin et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: